Analyst Edward Nash from Canaccord Genuity maintained a Buy rating on Travere Therapeutics (TVTX – Research Report) and keeping the price ...

Wells Fargo analyst Mohit Bansal has maintained their neutral stance on TVTX stock, giving a Hold rating yesterday. Mohit Bansal has given his ...

Travere Therapeutics stock popped Wednesday after a group of experts suggested an alternative means of measuring the success of FSGS drugs.

We recently published a list of 10 Best Biotech Stocks To Buy Under $20. In this article, we are going to take a look at ...

Travere Therapeutics Inc (TVTX) reports a 77% increase in net product sales, driven by FILSPARI's performance, while ...

Travere Therapeutics (TVTX) stock fell after announcing a pause in enrollments for its Phase 3 HARMONY Study for enzyme ...

Travere (TVTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Travere Therapeutics offers rare kidney disease treatments with FDA-approved Filspari. Check out why I deem TVTX stock as a ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 1.51% of ...

Shortly after winning full FDA approval for its rare kidney disease drug Filspari, San Diego’s Travere Therapeutics has run ...

The San Diego company said patients currently enrolled in pegtibatinase studies will continue to receive study medication from small-scale batches that aren't affected by the scale-up process, but it ...

Travere Therapeutics (NASDAQ:TVTX) underwent analysis by 14 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ...